Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRS034
MIFTS: 52

Parasitic Helminthiasis Infectious Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Parasitic Helminthiasis Infectious Disease

About this section

MalaCards integrated aliases for Parasitic Helminthiasis Infectious Disease:

Name: Parasitic Helminthiasis Infectious Disease 11 14
Helminthiasis 11 19 75 53 43 16 71
Intestinal Helminthiasis 19 71 33
Intestinal Infection Due to Class Cestoda and/or Class Trematoda and/or Phylum Nemata 33
Intestinal Worms Nos 33
Helminth Infections 14
Parasitic Enteritis 33
Helminth Infection 11
Metazoal Dysentery 33
Worm Infections 19
Worm Infection 11
Helminthosis 11

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:883
ICD9CM 34 120-129.99
MeSH 43 D006373
NCIt 49 C84751
SNOMED-CT 68 187518006
ICD10 31 B82.0 B83.9
ICD11 33 1979821488
UMLS 71 C0018889 C0348287
Sources

Summaries for Parasitic Helminthiasis Infectious Disease

About this section

Disease Ontology: 11 A parasitic infectious disease that occurs when part of the body is infested with parasitic worms such as cestodes, nematodes and trematodes.

MalaCards based summary: Parasitic Helminthiasis Infectious Disease, also known as helminthiasis, is related to angiostrongyliasis and mesocestoidiasis. An important gene associated with Parasitic Helminthiasis Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Artemether and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and b cells, and related phenotypes are homeostasis/metabolism and immune system

GARD: 19 A parasitic infection characterized by the infestation with worms, mainly in the intestine.

Wikipedia: 75 Helminthiasis, also known as worm infection, is any macroparasitic disease of humans and other animals... more...
Sources

Related Diseases for Parasitic Helminthiasis Infectious Disease

About this section

Diseases related to Parasitic Helminthiasis Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 763)
# Related Disease Score Top Affiliating Genes
1 angiostrongyliasis 32.7 MT-CO1 IL5 IL13
2 mesocestoidiasis 32.7 MT-ND1 MT-CO1
3 ancylostomiasis 32.6 MT-ND1 MT-CO1 IL5
4 enterobiasis 32.6 STH MT-CO1 IL5 IL4
5 clonorchiasis 32.6 STH MT-CO1 IL10
6 echinostomiasis 32.6 MT-ND1 MT-CO1
7 hymenolepiasis 32.6 STH MT-CO1
8 diphyllobothriasis 32.6 MT-ND1 MT-CO1
9 gnathomiasis 32.6 STH MT-CO1
10 fascioliasis 32.6 MT-ND1 MT-CO1 IL4 IL10
11 paragonimiasis 32.6 STH RNASE3 MT-CO1 IL5 IL13
12 coenurosis 32.6 MT-ND1 MT-CO1
13 echinococcosis 32.6 RNASE3 MT-CO1 IL5 IL17A IL10
14 dracunculiasis 32.5 STH MT-CO1
15 trichuriasis 32.5 STH SERPINA3 IL9 IL13 IL10
16 toxocariasis 32.5 STH RNASE3 IL5 IL4 IL13 IL10
17 strongyloidiasis 32.4 STH MT-CO1 IL5 IL4 IL13 IL10
18 sparganosis 32.4 MT-ND1 MT-CO1
19 filariasis 32.4 STH SERPINA3 MT-CO1 IL5 IL4 IL13
20 taeniasis 32.4 STH MT-ND1 MT-CO1 IL5 IL4 IL13
21 ascaris lumbricoides infection 32.3 STH MT-ND1 IL9 IL5 IL4 IL13
22 trichinosis 32.3 TSLP IL9 IL5 IL4 IL17A IL13
23 schistosomiasis 32.2 STAT6 RNASE3 IL9 IL5 IL4 IL33
24 hypereosinophilic syndrome 31.3 RNASE3 IL9 IL5 IL4 IL13 IL10
25 deficiency anemia 31.1 SERPINA3 IL10 ICOSLG H2AC18 CD4 CCR6
26 loiasis 31.1 STH IL5 IL4 IL13 IL10
27 nutritional deficiency disease 31.1 SERPINA3 H2AC18 CCR6
28 giardiasis 31.0 STH IL17A IL10 H2AC18 CD4
29 ige responsiveness, atopic 31.0 STAT6 RNASE3 IL5 IL4 IL13 IL10
30 autoimmune disease 31.0 IL9 IL5 IL4 IL17A IL13 IL10
31 onchocerciasis 30.9 STH SERPINA3 RNASE3 IL5 IL4 IL13
32 filarial elephantiasis 30.9 STH MT-CO1 IL9 IL5 IL4 IL13
33 gastroenteritis 30.8 RNASE3 IL5 IL4 IL10
34 inflammatory bowel disease 1 30.8 IL17A IL10 H2AC18 CCR6
35 type 1 diabetes mellitus 30.8 IL4 IL17A IL10 ICOSLG CCR6
36 mycobacterium tuberculosis 1 30.7 SERPINA3 MIR21 IL4 IL17A IL10 ICOSLG
37 cysticercosis 30.7 STH MT-ND1 MT-CO1 IL5 IL4 IL10
38 pulmonary eosinophilia 30.7 RNASE3 IL5 IL4 IL13
39 pneumonia 30.7 IL5 IL4 IL17A IL13 IL10
40 colitis 30.6 STAT6 MIR21 IL5 IL4 IL17A IL13
41 urinary schistosomiasis 30.6 STH RNASE3 IL5 IL4 IL13 IL10
42 tetanus 30.6 IL9 IL5 IL4 IL13 IL10
43 ulcerative colitis 30.6 STAT6 IL5 IL4 IL17A IL13 IL10
44 dermatitis 30.6 TSLP RNASE3 IL5 IL4 IL33 IL17A
45 cutaneous leishmaniasis 30.6 IL5 IL4 IL13 IL10 H2AC18 CD4
46 inflammatory bowel disease 30.6 STAT6 SERPINA3 RNASE3 IL5 IL4 IL17A
47 alveolar echinococcosis 30.6 MT-ND1 MT-CO1 IL5 IL4 IL10 CD4
48 allergic asthma 30.5 TSLP STAT6 RNASE3 IL9 IL5 IL4
49 aspergillosis 30.5 IL5 IL4 IL10 CCR6
50 systemic lupus erythematosus 30.5 MIR21 IL5 IL4 IL17A IL13 IL10

Graphical network of the top 20 diseases related to Parasitic Helminthiasis Infectious Disease:



Diseases related to Parasitic Helminthiasis Infectious Disease
Sources

Symptoms & Phenotypes for Parasitic Helminthiasis Infectious Disease

About this section

MGI Mouse Phenotypes related to Parasitic Helminthiasis Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 CCR6 CD4 FAM53B ICOSLG IL10 IL13
2 immune system MP:0005387 10 CCR6 CD4 ICOSLG IL10 IL13 IL17A
3 digestive/alimentary MP:0005381 9.91 CD4 IL10 IL13 IL17A IL33 IL4
4 respiratory system MP:0005388 9.56 IL10 IL13 IL17A IL33 IL4 IL5
5 hematopoietic system MP:0005397 9.47 CCR6 CD4 FAM53B ICOSLG IL10 IL13
Sources

Drugs & Therapeutics for Parasitic Helminthiasis Infectious Disease

About this section

Drugs for Parasitic Helminthiasis Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artemether Approved Phase 4 71963-77-4 68911 9796294
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
6
Iron Approved Phase 4 7439-89-6 29936
7
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
8
Copper Approved, Investigational Phase 4 7440-50-8 27099
9
Mecobalamin Approved, Investigational Phase 4 13422-55-4
10
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
11
Tocopherol Approved, Investigational Phase 4 1406-66-2
12
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
13
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
14
Pyrantel Approved, Vet_approved Phase 4 15686-83-6
15
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 4 14769-73-4 26879
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
18
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
19
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
20
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
21
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
23
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
24
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
26
Cobalamin Experimental Phase 4 13408-78-1 6857388
27
Tocotrienol Investigational Phase 4 6829-55-6 9929901
28 Antimalarials Phase 4
29 Artemisinins Phase 4
30 Artemether, Lumefantrine Drug Combination Phase 4
31 Chrysarobin Phase 4
32 Vitamins Phase 4
33 Folate Phase 4
34 Vitamin B9 Phase 4
35 Vitamin B6 Phase 4
36 Vitamin B3 Phase 4
37 Trace Elements Phase 4
38 Nicotinic Acids Phase 4
39
Vitamin B2 Phase 4
40 Vitamin B12 Phase 4
41 Vitamin B1 Phase 4
42 Vitamin B Complex Phase 4
43 Vitamin B 6 Phase 4
44 Vitamin B 12 Phase 4
45 Copper Supplement Phase 4
46 Thiamin Phase 4
47 Micronutrients Phase 4
48 Retinol palmitate Phase 4
49 Tocotrienols Phase 4
50 Tocopherols Phase 4

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project Completed NCT01088958 Phase 4
3 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
4 The Impact of Different Treatment Strategies on the Transmission Dynamics of Soil-transmitted Helminths: a Cluster Randomised Trial in Kenya Completed NCT02397772 Phase 4 albendazole
5 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole
6 Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon Completed NCT04326868 Phase 4 Benzimidazole Anthelmintic
7 Chengdu Women's and Children's Central Hospital Completed NCT02675140 Phase 4 ZENTEL;ZENTEL and Vitamin A Soft Capsules
8 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
9 Longitudinal Study of Efficacy of Standard Albendazole Treatment Versus Levamisole/Pyrantel Pamoate on Soil Transmitted Helminth Infections Completed NCT00659997 Phase 4 Albendazole;Levamisole
10 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam Withdrawn NCT02597556 Phase 4 Albendazole;Placebo
11 Intestinal Microbiome Post-Azythromycin/Albendazole Treatment Withdrawn NCT03032042 Phase 4 Azithromycin;Albendazole;Delayed treatment
12 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
13 A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects Completed NCT02034162 Phase 3 Mebendazole;Placebo
14 Efficacy and Safety of Moxidectin and Albendazole Compared to Ivermectin and Albendazole Co-administration in Adolescents Infected With Trichuris Trichiura: a Randomized Controlled Trial Completed NCT04700423 Phase 2, Phase 3 moxidectin (8 mg) / albendazole (400 mg);ivermectin (200 µg/kg) / albendazole (400 mg);ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL];ivermectin (200 µg/kg);moxidectin (8 mg)
15 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections Completed NCT01350271 Phase 3 Mebendazole polymorph A and C 500 mg;Mebendazole polymorph C;Placebo
16 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) DeWorm3 Project Recruiting NCT03014167 Phase 3 Albendazole
17 An Adaptive Phase II/III SingleBlinded, Randomized, MultiCentre, ParallelGroup, Active Controlled, Superiority Study to Evaluate the Safety and Efficacy of a Single Day or 3day Single Dose of an ALBENDAZOLE IVERMECTIN Coformulation vs ALBENDAZOLE for the Treatment of SoilTransmitted Helminth Infections (Trichuris Trichiura, Hookworm, Strongyloides Stercoralis) in Paediatric and Young Adult Population Recruiting NCT05124691 Phase 2, Phase 3 Albendazole
18 Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients Completed NCT04041453 Phase 2 Ivermectin;Albendazole
19 Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis Active, not recruiting NCT03441893 Phase 1, Phase 2 Nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg;Placebo tabletes
20 An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Withdrawn NCT02636803 Phase 2 oxfendazole;albendazole
21 The Impact of Health Education in Controlling Soil-transmitted Helminthiasis Among Orang Asli Schoolchildren Completed NCT01640626 Phase 1
22 Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA, Abbott Laboratórios do Brasil Ltda, Brazil) Completed NCT03173742 Phase 1 T1, T2, T3;T1,T3,T2;T2,T1,T3;T2,T3,T1;T3,T1,T2;T3,T2,T1
23 Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole and Its Metabolites in Non-infected Human Volunteers. Completed NCT03192449 Phase 1 Albendazole.
24 A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males Completed NCT01755637 Phase 1 Albendazole
25 A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers Completed NCT03035760 Phase 1 Oxfendazole
26 Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area Unknown status NCT01308268 Ivermectin + Albendazole
27 Re-infection Rates of Soil-transmitted Helminth Infections Among School-aged Children Following a Single or a 4-monthly Health Hygiene Education: an Open Label Clinical Trial Unknown status NCT04227834
28 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole
29 Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants Unknown status NCT02714348
30 Assessing the Health Impact of a Combined Water and Sanitation Intervention in Rural Odisha, India Unknown status NCT02441699
31 The Longevity of Trichuris Trichiura Colonization Completed NCT04227925
32 Mucosal and Systemic Immune Modulation From Trichuris Suis in a Self-infected Individual Completed NCT03079700
33 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593
34 Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Completed NCT00463931
35 Diagnosis of Neglected Tropical Diseases (NTDs) in Patients Presenting With Persistent Digestive Disorders (≥2 Weeks) in Côte d'Ivoire, Indonesia, Mali and Nepal Completed NCT02105714
36 Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression Completed NCT00507221 Albendazole;Praziquantel;Current standard of care in Kenya
37 Empiric Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Trial in Subjects Co-Infected With Helminths and Leishmania Brasiliensis Completed NCT00469495 Anti-helminthic;meglumine antimony
38 Impact of Repeated Anthelminthic Treatment on Malaria in School Children: an Individual Randomized, Double-blind, Placebo-controlled Trial in Western Kenya Completed NCT01658774 Albendazole
39 A Controlled Before and After Study to Measure the Effect of an Urban Sanitation Intervention on Child Health, in Low-income Neighborhoods of Maputo, Mozambique Completed NCT02362932
40 Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding. Completed NCT00130910 Albendazole;Placebo
41 Langherhans' Cell Function and Inflammatory Responses in Skin of Volunteers Using the Suction Blister Technique Completed NCT00004996
42 Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health Completed NCT02396407
43 Assessment of Drug Efficacy of Albendazole Bought on Local Market Against Soil-transmitted Helminth Infections in School Children in Jimma, Ethiopia Completed NCT02420574 albendazole BENDEX;albendazole OVIS
44 Relative Efficacy of Two Regimens of Ante-helminthic Treatment Completed NCT00367627 Albendazole
45 Development of Urinary-based Assay to Determine Treatment Coverage With Albendazole in Mass Drug Administration Programs Completed NCT04041427 Albendazole Pill
46 Mucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected Individual Completed NCT02399683
47 Impact of Community-Led Total Sanitation on the Control of Taenia Solium and Soil Transmitted Helminths in the Eastern Province of Zambia Completed NCT01368354
48 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
49 Effects of Intermittent Iron and Vitamin A Supplementation on Nutritional Status and Development of Schoolchildren in Arba Minch Zuria District, Ethiopia. Completed NCT04137354
50 Effectiveness of a Post-deworming Education Intervention to Reduce Soil-transmitted Helminth Infections and Absenteeism in Grade 5 School-children in a Community of Extreme Poverty, Peruvian Amazon Completed NCT01085799

Search NIH Clinical Center for Parasitic Helminthiasis Infectious Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Albendazole
Antihelminthic [EPC]
Mebendazole
Niclosamide
Oxamniquine
Praziquantel
Thiabendazole

Cochrane evidence based reviews: helminthiasis

Sources

Genetic Tests for Parasitic Helminthiasis Infectious Disease

About this section
Sources

Anatomical Context for Parasitic Helminthiasis Infectious Disease

About this section

Organs/tissues related to Parasitic Helminthiasis Infectious Disease:

MalaCards : T Cells, Skin, B Cells, Small Intestine, Bone Marrow, Lymph Node, Lung
Sources

Publications for Parasitic Helminthiasis Infectious Disease

About this section

Articles related to Parasitic Helminthiasis Infectious Disease:

(show top 50) (show all 6195)
# Title Authors PMID Year
1
Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis. 53 62
19471606 2008
2
[Toxocariasis in children--difficult clinical problem]. 53 62
18807488 2008
3
Eosinophil cationic protein as a possible marker of active human Toxocara infection. 53 62
11703226 2001
4
Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. 53 62
11169280 2000
5
Hyperimmunoglobulinemia E in the absence of atopy and filarial infection: the Huaorani of Ecuador. 53 62
11191097 2000
6
Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. 53 62
11060486 2000
7
Possible relationship between allergic disease and infection by Giardia lamblia. 53 62
8452315 1993
8
Meat production, quality, and oxidative shelf-life of Haemonchus-parasitised and non-parasitised lambs fed incremental levels of sericea lespedeza substituted for lucerne. 62
36283161 2023
9
Is there any change in the prevalence of intestinal or cardiopulmonary parasite infections in companion animals (dogs and cats) in Germany between 2004-2006 and 2015-2017? An assessment of the impact of the first ESCCAP guidelines. 62
36335832 2022
10
Green vegetable juice as a potential source of human fascioliasis in Korea. 62
36277099 2022
11
Tongue worm (subclass: Pentastomida) infection and treatment in two domesticated reptiles - A case report. 62
35777656 2022
12
First Report on Molecular Identification of Moniezia expansa in Sheep from Mannavanur, Palani Hills, Tamil Nadu, India. 62
36074238 2022
13
Can helminth and malaria infections affect sex ratio at birth in sub-Saharan Africa? Ideas and hypothesis. 62
35947958 2022
14
Factors determining preventive chemotherapy uptake against soil-transmitted helminthiasis among school-age children in Ghana. 62
36264508 2022
15
Compounding vulnerabilities: Syndemics and the social determinants of disease in the past. 62
36215930 2022
16
An update of intestinal helminth infections among urban slum communities in Bangladesh. 62
36105668 2022
17
Iron deficiency and soil-transmitted helminth infection: classic and neglected connections. 62
36258094 2022
18
Implementation of a targeted treatment strategy for the sustainable control of Ascaridia galli infections in laying hens. 62
35663271 2022
19
An investigation of Mycobacterium bovis and helminth coinfection in the European badger Meles meles. 62
36444386 2022
20
The Impact of Helminth Coinfection on Innate and Adaptive Immune Resistance and Disease Tolerance during Toxoplasmosis. 62
36426972 2022
21
Sex-the most underappreciated variable in research: insights from helminth-infected hosts. 62
36397174 2022
22
Helminth parasites are associated with reduced survival probability in young red deer. 62
36052566 2022
23
Luna Virus and Helminths in Wild Mastomys natalensis in Two Contrasting Habitats in Zambia: Risk Factors and Evidence of Virus Dissemination in Semen. 62
36422597 2022
24
A New Comestible Formulation of Parasiticide Fungi to Reduce the Risk of Soil-Transmitted Helminth Infections in a Canine Shelter. 62
36422641 2022
25
SLC7A8 is a key amino acids supplier for the metabolic programs that sustain homeostasis and activation of type 2 innate lymphoid cells. 62
36343258 2022
26
A copro-antigen ELISA for the detection of ascarid infections in chickens. 62
36108471 2022
27
Pumpkin seeds, lemongrass essential oil and ripleaf leaves as feed additives for Ascaridia galli infected laying hens. 62
36449119 2022
28
Intestinal Helminth Infections in Ghanaian Children from the Ashanti Region between 2007 and 2008-A Retrospective Cross-Sectional Real-Time PCR-Based Assessment. 62
36422925 2022
29
Insights into the Role of Compendial/Biorelevant Media on the Supersaturation Behaviour of Drug Combination (Drug-Drug Interaction) and Precipitation Inhibition by Polymers. 62
36380100 2022
30
An overview of human helminthioses in Vietnam: Their prevention, control and lessons learnt. 62
36375522 2022
31
Gut bacteriome and metabolome of Ascaris lumbricoides in patients. 62
36376367 2022
32
Medicinal Plant Preparations Administered by Botswana Traditional Health Practitioners for Treatment of Worm Infections Show Anthelmintic Activities. 62
36365400 2022
33
Proteomic analysis of the excretory-secretory products from Strongyloides venezuelensis infective larvae: new insights for the immunodiagnosis of human strongyloidiasis. 62
36044090 2022
34
Clostridia isolated from helminth-colonized humans promote the life cycle of Trichuris species. 62
36450245 2022
35
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. 62
35594896 2022
36
Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. 62
36375598 2022
37
Immunological Interactions between Intestinal Helminth Infections and Tuberculosis. 62
36359526 2022
38
Helminths and Bacterial Microbiota: The Interactions of Two of Humans' "Old Friends". 62
36362143 2022
39
Gastrointestinal worms and bacteria: From association to intervention. 62
36300732 2022
40
The synthesis and antibacterial activity study of ruthenium-based metallodrugs with a membrane-disruptive mechanism against Staphylococcus aureus. 62
36112764 2022
41
A New Role for Old Friends: Effects of Helminth Infections on Vaccine Efficacy. 62
36297220 2022
42
Long-Term Trend Analysis of Major Human Helminth Infections - Guangdong Province, China, 1988-2021. 62
36426289 2022
43
Strongyloidiasis - diagnostic and therapeutic dilemmas in hyperinfection patients: a case series. 62
36263595 2022
44
Development and validation of a quantitative PCR for the detection of Guinea worm (Dracunculus medinensis). 62
36206300 2022
45
Echinococcus granulosus sensu stricto and antigen B may decrease inflammatory bowel disease through regulation of M1/2 polarization. 62
36289514 2022
46
Contribution of the Immune Response in the Ileum to the Development of Diarrhoea caused by Helminth Infection: Studies with the Sheep Model. 62
35576023 2022
47
Swiss-Chinese Cooperation in Tropical Medicine: The Role of Professor Marcel Tanner. 62
36278582 2022
48
Interleukin-33 deficiency prevents biliary injuries and repairments caused by Clonorchis sinensis via restraining type 2 cytokines. 62
36271450 2022
49
Expansion of Opportunistic Enteric Fungal Pathogens and Occurrence of Gut Inflammation in Human Liver Echinococcosis. 62
36098525 2022
50
Prevalence of Intestinal Helminth Coinfection in Drug-Resistant Tuberculosis in Uganda. 62
36324329 2022
Sources

Variations for Parasitic Helminthiasis Infectious Disease

About this section
Sources

Expression for Parasitic Helminthiasis Infectious Disease

About this section
Search GEO for disease gene expression data for Parasitic Helminthiasis Infectious Disease.
Sources

Pathways for Parasitic Helminthiasis Infectious Disease

About this section

Pathways related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.88 CCR6 CD4 ICOSLG IL10 IL13 IL17A
2
ERK Signaling 64
Show member pathways
 13.75 CCR6 CD4 IL10 IL13 IL17A IL4
3
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.58 CCR6 CD4 IL10 IL13 IL17A IL33
4
TGF-Beta Pathway 64
Show member pathways
 13.47 STAT6 IL9 IL5 IL4 IL17A IL13
5
Akt Signaling 64
Show member pathways
 13.36 STAT6 IL9 IL5 IL4 IL17A IL13
6
PAK Pathway 64
Show member pathways
 13.25 IL9 IL5 IL4 IL17A IL13 IL10
7
Cytokine Signaling in Immune system 66
Show member pathways
 13.24 TSLP STAT6 IL9 IL5 IL4 IL33
8
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.59 IL10 IL13 IL17A IL4 IL5 IL9
9
T-cell activation SARS-CoV-2 74
Show member pathways
 12.1 IL5 IL4 IL17A IL10 CD4
10
Neuroinflammation and glutamatergic signaling 74
12.05 STAT6 IL4 IL13 IL10
11
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.96 IL5 IL4 IL10 CD4
12
Interleukin-4 and Interleukin-13 signaling 66
11.94 STAT6 IL4 IL17A IL13 IL10
13
Allograft rejection 74
11.86 IL5 IL4 IL17A IL13 IL10
14
Th17 Differentiation 65
Show member pathways
 11.78 IL4 IL17A CD4
15
Th17 cell differentiation pathway 74
11.71 STAT6 IL4 IL17A CD4
16
Glucocorticoid receptor regulatory network 61
11.7 IL5 IL4 IL13
17
Extrafollicular B cell activation by SARS-CoV-2 74
11.66 IL4 IL10 ICOSLG
18
AP-1 transcription factor network 61
11.65 IL5 IL4 IL10
19
IL4-mediated signaling events 61
11.63 STAT6 IL5 IL4 IL10
20
Inflammatory bowel disease signaling 74
Show member pathways
 11.6 IL10 IL13 IL4 IL5 STAT6
21
Lung fibrosis 74
11.59 IL5 IL4 IL13
22
Interactions between immune cells and microRNAs in tumor microenvironment 74
11.47 STAT6 MIR21 IL4
23
Cytokines and inflammatory response 74
11.23 IL5 IL4 IL13 IL10 CD4
24
Innate Lymphoid Cells Differentiation 65
11.23 TSLP IL9 IL5 IL4 IL33 IL17A
25
Th2 Differentiation 65
11.22 STAT6 IL9 IL5 IL4 IL33 IL13
26
Development and heterogeneity of the ILC family 74
11.2 IL13 IL17A IL33 IL4 IL5 IL9
27
Immune infiltration in pancreatic cancer 74
11.15 IL5 IL4 IL17A IL13 IL10
28
OX40 Pathway 64
11.07 IL9 IL5 IL4 IL13 IL10
29
G-protein signaling_Rap2B regulation pathway 22
10.98 IL10 IL13 IL17A IL4 IL5 IL9
30
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
10.78 IL9 IL5 IL4 IL13
Sources

GO Terms for Parasitic Helminthiasis Infectious Disease

About this section

Cellular components related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.64 TSLP SERPINA3 RNASE3 MIR21 IL9 IL5

Biological processes related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.48 CCR6 CD4 ICOSLG IL10 IL13 IL4
2 positive regulation of B cell proliferation GO:0030890 10.02 IL5 IL4 IL13
3 positive regulation of interleukin-10 production GO:0032733 10.01 TSLP IL4 IL13
4 defense response to Gram-negative bacterium GO:0050829 9.98 CD4 IL17A RNASE3 TSLP
5 negative regulation of endothelial cell apoptotic process GO:2000352 9.97 IL4 IL13 IL10
6 positive regulation of macrophage activation GO:0043032 9.88 IL33 IL13 IL10
7 positive regulation of interleukin-13 production GO:0032736 9.85 TSLP IL4 IL33
8 regulation of isotype switching GO:0045191 9.81 IL4 IL10
9 positive regulation of MHC class II biosynthetic process GO:0045348 9.8 IL4 IL33 IL10
10 immune response GO:0006955 9.8 IL9 IL5 IL4 IL17A IL13 IL10
11 negative regulation of complement-dependent cytotoxicity GO:1903660 9.78 IL4 IL13
12 positive regulation of isotype switching to IgE isotypes GO:0048295 9.76 STAT6 IL4
13 positive regulation of interleukin-5 production GO:0032754 9.73 TSLP IL9 IL33
14 type 2 immune response GO:0042092 9.63 IL10 IL33 IL4
15 positive regulation of immunoglobulin production GO:0002639 9.23 IL5 IL33 IL13 IL10

Molecular functions related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.53 TSLP IL9 IL5 IL4 IL33 IL17A
2 cytokine receptor binding GO:0005126 9.13 IL9 IL4 IL13
Sources

Sources for Parasitic Helminthiasis Infectious Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....